CRISPR Therapeutics AG
Index- P/E14.54 EPS (ttm)3.60 Insider Own0.50% Shs Outstand77.10M Perf Week-3.64%
Market Cap4.07B Forward P/E- EPS next Y-7.56 Insider Trans0.00% Shs Float76.26M Perf Month-8.54%
Income311.60M PEG- EPS next Q-2.23 Inst Own61.40% Short Float13.30% Perf Quarter-1.63%
Sales915.40M P/S4.44 EPS this Y188.80% Inst Trans7.81% Short Ratio7.05 Perf Half Y-35.00%
Book/sh29.12 P/B1.80 EPS next Y15.10% ROA11.30% Target Price116.82 Perf Year-54.97%
Cash/sh28.60 P/C1.83 EPS next 5Y- ROE12.80% 52W Range42.51 - 169.76 Perf YTD-30.88%
Dividend- P/FCF9.82 EPS past 5Y35.00% ROI15.50% 52W High-69.14% Beta1.93
Dividend %- Quick Ratio19.90 Sales past 5Y181.60% Gross Margin- 52W Low23.22% ATR4.17
Employees473 Current Ratio19.90 Sales Q/Q80.00% Oper. Margin34.10% RSI (14)47.35 Volatility7.11% 8.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-54.10% Profit Margin34.00% Rel Volume0.76 Prev Close54.71
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout0.00% Avg Volume1.44M Price52.38
Recom2.20 SMA202.03% SMA50-10.22% SMA200-35.05% Volume1,090,345 Change-4.26%
Apr-28-22Initiated Credit Suisse Neutral $78
Dec-07-21Initiated Cowen Market Perform
Oct-19-21Initiated SVB Leerink Outperform $126
Jun-14-21Upgrade Citigroup Sell → Neutral $55 → $132
Apr-21-21Upgrade Jefferies Hold → Buy $172
Mar-04-21Initiated JMP Securities Mkt Outperform $160
Dec-10-20Reiterated Needham Buy $105 → $170
Dec-10-20Reiterated Chardan Capital Markets Buy $110 → $166
Dec-10-20Downgrade Jefferies Buy → Hold
Dec-07-20Downgrade Wells Fargo Overweight → Equal Weight $145
Oct-23-20Initiated RBC Capital Mkts Sector Perform $110
Oct-05-20Initiated BofA Securities Buy $110
Jul-28-20Reiterated Needham Buy $84 → $105
Jul-14-20Initiated SunTrust Buy $140
Jun-15-20Reiterated Canaccord Genuity Buy $80 → $84
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
May-18-22 09:06AM  
May-16-22 04:01PM  
May-13-22 11:52AM  
May-12-22 04:04PM  
May-10-22 10:30AM  
May-09-22 05:15PM  
May-06-22 10:37AM  
May-04-22 08:00AM  
May-02-22 06:02AM  
Apr-27-22 09:18AM  
Apr-26-22 06:45AM  
Apr-22-22 02:58PM  
Apr-19-22 06:20AM  
Apr-14-22 10:03AM  
Apr-13-22 10:45AM  
Apr-12-22 04:01PM  
Apr-07-22 04:01PM  
Apr-06-22 07:47AM  
Mar-29-22 08:15AM  
Mar-26-22 08:00AM  
Mar-24-22 06:00PM  
Mar-23-22 08:28AM  
Mar-21-22 02:25PM  
Mar-18-22 05:50PM  
Mar-17-22 11:30AM  
Mar-16-22 10:37AM  
Mar-11-22 07:49PM  
Mar-10-22 06:00PM  
Mar-09-22 02:58PM  
Mar-08-22 05:31PM  
Mar-04-22 05:50PM  
Mar-01-22 08:00PM  
Feb-28-22 08:59AM  
Feb-23-22 03:07PM  
Feb-18-22 05:31AM  
Feb-16-22 11:48AM  
Feb-15-22 05:25PM  
Feb-10-22 03:33PM  
Feb-09-22 08:00AM  
Feb-08-22 03:00PM  
Feb-07-22 06:00PM  
Feb-05-22 03:56PM  
Feb-02-22 01:38PM  
Feb-01-22 01:38PM  
Jan-31-22 09:38AM  
Jan-30-22 09:31AM  
Jan-28-22 06:10PM  
Jan-26-22 06:00PM  
Jan-25-22 05:38PM  
Jan-22-22 08:58AM  
Jan-21-22 05:38PM  
Jan-20-22 10:44AM  
Jan-19-22 09:38PM  
Jan-18-22 11:00AM  
Jan-16-22 06:47AM  
Jan-13-22 03:56PM  
Jan-11-22 01:52PM  
Jan-10-22 08:17AM  
Jan-08-22 12:59PM  
Jan-07-22 06:00PM  
Jan-03-22 06:00AM  
Dec-31-21 11:40AM  
Dec-30-21 06:52AM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerDec 20Option Exercise1.8117,75032,128279,085Dec 22 08:00 PM
KASINGER JAMES R.General Counsel and SecretaryDec 02Option Exercise13.627,34299,99836,512Dec 03 08:00 PM
Kulkarni SamarthChief Executive OfficerOct 15Option Exercise1.8133,00059,730219,932Oct 18 08:00 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 06Option Exercise17.7525,000443,75026,891Aug 10 08:00 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 06Sale138.5225,0003,462,9261,891Aug 10 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 05Option Exercise12.5728,500358,245216,219Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 05Sale128.9828,5003,675,939187,719Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 04Option Exercise12.571,50018,855189,219Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 04Sale125.021,500187,530187,719Aug 06 08:00 PM
Bolzon Bradley J PhDDirectorJul 19Sale126.4310,0001,264,348148,831Jul 21 05:21 PM
Novak RodgerPresidentJun 30Sale165.0025,0004,125,000573,007Jul 01 05:43 PM
Bolzon Bradley J PhDDirectorJun 28Sale152.4810,0001,524,799158,831Jun 30 06:38 PM
Bolzon Bradley J PhDDirectorJun 28Sale152.4820,3753,106,7830Jun 30 06:38 PM
Novak RodgerPresidentJun 21Sale128.6225,0003,215,458623,007Jun 23 05:54 PM
Kulkarni SamarthChief Executive OfficerJun 15Option Exercise12.5730,000377,100217,719Jun 17 05:44 PM
Kulkarni SamarthChief Executive OfficerJun 15Sale126.4330,0003,792,804187,719Jun 17 05:44 PM
Bolzon Bradley J PhDDirectorJun 11Sale126.6110,0001,266,11820,375Jun 15 04:41 PM